UK Markets closed

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
33.38+3.35 (+11.16%)
At close: 3:37PM BST

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000

Full-time employees235

Key executives

NameTitlePayExercisedYear born
Mr. James C. MullenChairman, Pres & CEO100.5kN/A1959
Ms. Michelle RobertsonCFO, Principal Accounting Officer, Treasurer & Assistant Sec.647.26kN/A1967
Dr. Lisa A. Michaels M.D.Exec. VP & Chief Medical Officer213.47kN/A1965
Dr. Feng ZhangCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George M. ChurchCo-Founder & Scientific Advisory Board MemberN/AN/A1954
Dr. J. Keith JoungCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. David R. LiuCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Mr. Harry R. Gill IIISr. VP of OperationsN/AN/A1961
Ms. Charlene SternSr. VP & Chief Legal OfficerN/AN/AN/A
Ms. Clare CarmichaelChief HR OfficerN/AN/A1960
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Editas Medicine, Inc.’s ISS governance QualityScore as of 30 April 2021 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.